Holen Sie sich die Stockscreener-App
184.68
1.08%
1.825
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt AZN?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$182.85
Offen:
$183.79
24-Stunden-Volumen:
736.39K
Relative Volume:
0.36
Marktkapitalisierung:
$286.50B
Einnahmen:
$60.48B
Nettoeinkommen (Verlust:
$10.40B
KGV:
55.46
EPS:
3.3297
Netto-Cashflow:
$8.05B
1W Leistung:
+0.75%
1M Leistung:
-9.41%
6M Leistung:
+107.46%
1J Leistung:
+173.54%
1-Tages-Spanne:
$183.79
$185.81
1-Wochen-Bereich:
$180.00
$185.81
52-Wochen-Spanne:
$66.16
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Compare AZN vs LLY, JNJ, ABBV, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
184.74 | 283.57B | 60.48B | 10.40B | 8.05B | 3.3297 |
LLY
Lilly Eli Co
|
989.14 | 845.77B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
221.68 | 532.77B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
203.81 | 356.49B | 62.82B | 3.60B | 19.98B | 2.0274 |
NVS
Novartis Ag Adr
|
146.20 | 278.64B | 54.66B | 13.58B | 16.05B | 7.0171 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-27 | Eingeleitet | Citigroup | Buy |
| 2025-10-27 | Fortgesetzt | Jefferies | Buy |
| 2025-10-16 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2025-04-15 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2025-02-13 | Hochstufung | UBS | Neutral → Buy |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-20 | Hochstufung | UBS | Sell → Neutral |
| 2024-11-06 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-09-13 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-04-16 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-02-08 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-01-16 | Fortgesetzt | UBS | Sell |
| 2024-01-03 | Herabstufung | Jefferies | Buy → Hold |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-09-25 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-12 | Hochstufung | UBS | Neutral → Buy |
| 2023-07-05 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-04-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-09-15 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | Hochstufung | Argus | Hold → Buy |
| 2022-06-14 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-11 | Hochstufung | DZ Bank | Sell → Hold |
| 2021-12-07 | Herabstufung | Jefferies | Buy → Hold |
| 2021-08-12 | Fortgesetzt | JP Morgan | Overweight |
| 2021-04-12 | Herabstufung | Argus | Buy → Hold |
| 2021-03-16 | Hochstufung | Jefferies | Hold → Buy |
| 2021-02-25 | Hochstufung | UBS | Neutral → Buy |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
| 2020-12-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | Hochstufung | UBS | Sell → Neutral |
| 2020-11-11 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2019-11-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-10-25 | Hochstufung | Liberum | Hold → Buy |
| 2019-04-02 | Herabstufung | UBS | Neutral → Sell |
| 2019-02-05 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2019-01-25 | Hochstufung | Shore Capital | Hold → Buy |
| 2018-12-11 | Fortgesetzt | Jefferies | Hold |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-08-16 | Herabstufung | Jefferies | Buy → Hold |
| 2018-03-19 | Hochstufung | Jefferies | Hold → Buy |
| 2018-02-06 | Bestätigt | Leerink Partners | Mkt Perform |
| 2018-02-05 | Bestätigt | Bernstein | Outperform |
| 2018-01-18 | Bestätigt | Leerink Partners | Mkt Perform |
| 2017-12-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-10-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | Hochstufung | Bernstein | Mkt Perform → Outperform |
Alle ansehen
Astrazeneca Plc Aktie (AZN) Neueste Nachrichten
AstraZeneca plc stock (GB0009895292): Beats Q1 Estimates, Analysts Raise Targets - AD HOC NEWS
AstraZeneca stock (US6549022043): Beats Q1 Estimates, Analysts Raise Targets - AD HOC NEWS
What next for AstraZeneca shares, after another cracking quarter? - MSN
AstraZeneca PLC stock (US6549022043): Strong 2025 results and pipeline momentum - AD HOC NEWS
AstraZeneca plc stock (GB0009895292): Pharma giant eyes growth amid pipeline progress and pricing pr - AD HOC NEWS
AstraZeneca wins FDA AdCom backing for Truqap in prostate cancer - MSN
First City Capital Management, Inc.'s AstraZeneca PLC(AZN) Holding History - GuruFocus
AstraZeneca (AZN) officer Sharma Mani granted additional Ordinary Shares - Stock Titan
Darren Sissons' Past Picks: AstraZeneca, Canadian Pacific Kansas City & Linde Plc - BNN Bloomberg
AstraZeneca plc Stock (GB0009895292): Strong Quarterly Results and Improved Outlook Support Shares - AD HOC NEWS
AstraZeneca PLC stock (US6549022043): Strong quarterly results and improved guidance lift AZN shares - AD HOC NEWS
Fund Update: 25,553,763 ASTRAZENECA (AZN) shares added to Legal & General Group Plc portfolio - Quiver Quantitative
AstraZeneca Advances Respiratory And Oncology Portfolio Within FTSE 350 - Kalkine Media
AstraZeneca stock price forecast: GBX13,000 support holds as AZN edges lower - Traders Union
Alteogen posts weaker Q1 as Korea tech deals lag last year’s AstraZeneca windfallCHOSUNBIZ - Chosunbiz
AstraZeneca Reps Fight To Keep Opt-Ins In Pay Bias Suit - Law360
PARP Inhibitors Clinical Trial Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - GlobeNewswire Inc.
AstraZeneca slides Thursday, underperforms market - MarketWatch
AstraZeneca and OMP Demonstrate Planning at the Speed of Change at Gartner Supply Chain Symposium/Xpo(TM) 2026 - marketscreener.com
Jazz, AstraZeneca, Astellas: Foreign Healthcare's strongest Quant picks (JAZZ:NASDAQ) - Seeking Alpha
Eli Lilly To Invest $4.5 Billion More In Indiana Manufacturing SitesAstraZeneca (NYSE:AZN), Johnson & - Benzinga
AstraZeneca PLC (NYSE:AZN) Q1 2026 Earnings Call Transcript - Insider Monkey
Buying pressure lifts AstraZeneca stock higher in today's trading - Traders Union
AstraZeneca stock edges higher as revenue surpasses forecasts at $15.29 billion - Traders Union
MSN Money - MSN
AstraZeneca Earnings Call: Oncology Strength, Pipeline Bets - TipRanks
AstraZeneca Shareholder Notice - TMX Newsfile
AstraZeneca Advances Early Liver-Function Trial That Could Shape Dosing for Future AZN Drugs - TipRanks
AZN Stock Quote Price and Forecast - CNN
AstraZeneca PLC Share PriceAZN, RNS News, Articles, Quotes, & Charts (LON:AZN) - Proactive Investors
Strong Results and Improved Guidance Lifted AstraZeneca PLC (AZN) - Yahoo Finance
AstraZeneca PLC (AZN) Stock Analysis: Unpacking A 21% Potential Upside Opportunity - DirectorsTalk Interviews
AstraZeneca stock drops 2.88% as shares remain below recent trading averages - Traders Union
Global pharma companies that have publicly announced Trump drug pricing agreements - Reuters
ASTRAZENECA : Bernstein reaffirms its Buy rating - marketscreener.com
Mixed FDA Votes On Truqap And Camizestrant Refocus AstraZeneca Oncology Risk - Yahoo Finance
Is AstraZeneca PLC (AZN) A Good Stock To Buy Now? - Insider Monkey
AstraZeneca invests £300 million in UK drug development sites - marketscreener.com
FTSE 100 Today Focus on BP plc (LSE:BP), Shell plc (LSE:SHEL) and AstraZeneca plc (LSE:AZN) - Kalkine Media
FIGURE 8 INVESTMENT STRATEGIES LLC's AstraZeneca PLC(AZN) Holding History - GuruFocus
Astrazeneca Plc $AZN Shares Sold by D.A. Davidson & CO. - MarketBeat
Alhambra Investment Management LLC's AstraZeneca PLC(AZN) Holding History - GuruFocus
AstraZeneca | Pharmaceuticals, Vaccines, & Facts | Britannica Money - Britannica
Transamerica MSCI EAFE Index VP's AstraZeneca PLC(LSE:AZN) Holding History - GuruFocus
Fidelity Sustainable International Equity Fund's AstraZeneca PLC(LSE:AZN) Holding History - GuruFocus
UK's FTSE 100 slips as losses in energy stocks and AstraZeneca weigh - marketscreener.com
AstraZeneca slides Friday, underperforms market - MarketWatch
UK's FTSE 100 Closes Lower; NatWest, AstraZeneca Shares Down - marketscreener.com
AstraZeneca updates voting rights and admits new shares to London Stock Exchange - Investing.com
Employee share plans add 14,807 AstraZeneca (AZN) shares to LSE - Stock Titan
FDA advisory committee does not support AstraZeneca’s camizestrant for breast cancer - Investing.com
Finanzdaten der Astrazeneca Plc-Aktie (AZN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.29%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):